
专业PIK3CA突变乳腺癌
Inavolisib改善PIK3CA突变晚期乳腺癌患者总生存期:INAVO120研究结果
By MedXY|2025年10月1日
Inavolisib联合帕博西利和氟维司群显著延长PIK3CA突变、激素受体阳性、HER2阴性晚期乳腺癌患者的总生存期,但增加某些毒性。
Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.